1. Home
  2. DFLI vs GLTO Comparison

DFLI vs GLTO Comparison

Compare DFLI & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Dragonfly Energy Holdings Corp. (NV)

DFLI

Dragonfly Energy Holdings Corp. (NV)

HOLD

Current Price

$2.49

Market Cap

49.0M

Sector

Technology

ML Signal

HOLD

Logo Galecto Inc.

GLTO

Galecto Inc.

HOLD

Current Price

$30.41

Market Cap

54.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DFLI
GLTO
Founded
2020
2011
Country
United States
Denmark
Employees
N/A
N/A
Industry
Electronic Components
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
49.0M
54.5M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
DFLI
GLTO
Price
$2.49
$30.41
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
3
Target Price
$22.50
$43.67
AVG Volume (30 Days)
450.0K
227.2K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$17.85
N/A
Revenue Next Year
$30.29
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.15
$2.01
52 Week High
$5.15
$38.33

Technical Indicators

Market Signals
Indicator
DFLI
GLTO
Relative Strength Index (RSI) 46.61 58.13
Support Level $2.16 $19.85
Resistance Level $2.88 $31.60
Average True Range (ATR) 0.29 2.94
MACD -0.03 0.59
Stochastic Oscillator 68.45 77.26

Price Performance

Historical Comparison
DFLI
GLTO

About DFLI Dragonfly Energy Holdings Corp. (NV)

Dragonfly Energy Holdings Corp is a manufacturer of non-toxic deep cycle lithium-ion batteries that are designed to displace lead acid batteries in a number of different storage applications and end markets including RV, marine vessel, and solar and off-grid industries, with disruptive solid-state cell technology currently under development. The company's deep cycle lithium iron phosphate ("LFP") batteries provide numerous advantages compared to incumbent products, such as lead-acid batteries. LFP batteries are non-toxic and environmentally friendly, do not rely on scarce or controversial metals, and are a cost-effective storage solution.

About GLTO Galecto Inc.

Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.

Share on Social Networks: